Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929)

PURPOSE: A Phase I clinical trial (GOG-9929) examined the safety and efficacy of adjuvant immune modulation therapy with the checkpoint inhibitor ipilimumab (anti-CTLA4) following chemoradiation therapy (CRT) for newly diagnosed node-positive human papillomavirus (HPV)-related cervical cancer. To be...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Clin Cancer Res
Auteurs principaux: DA SILVA, Diane M., ENSERRO, Danielle M., MAYADEV, Jyoti S., SKEATE, Joseph G., MATSUO, Koji, PHAM, Huyen Q., LANKES, Heather A., MOXLEY, Katherine M., GHAMANDE, Sharad A., LIN, Yvonne G., SCHILDER, Russell J., BIRRER, Michael J., KAST, W. Martin
Format: Artigo
Langue:Inglês
Publié: 2020
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7642021/
https://ncbi.nlm.nih.gov/pubmed/32816895
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-0776
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires